发明申请
US20090111794A1 Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase
有权
芳基取代的桥连或稠合二胺作为白三烯A4水解酶的调节剂
- 专利标题： Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase
- 专利标题（中）： 芳基取代的桥连或稠合二胺作为白三烯A4水解酶的调节剂
-
申请号： US12291018申请日： 2008-10-30
-
公开(公告)号： US20090111794A1公开(公告)日： 2009-04-30
- 发明人: Genesis M. Bacani , Scott D. Bembenek , Wendy Eccles , James P. Edwards , Matthew T. Epperson , Laurent Gomez , Cheryl A. Grice , Aaron M. Kearney , Adrienne M. Landry-Bayle , Alice Lee-Dutra , Kelly J. McClure , Taraneh Mirzadegan , Alejandro Santillan, JR.
- 申请人： Genesis M. Bacani , Scott D. Bembenek , Wendy Eccles , James P. Edwards , Matthew T. Epperson , Laurent Gomez , Cheryl A. Grice , Aaron M. Kearney , Adrienne M. Landry-Bayle , Alice Lee-Dutra , Kelly J. McClure , Taraneh Mirzadegan , Alejandro Santillan, JR.
- 主分类号： A61K31/55
- IPC分类号： A61K31/55 ; C07D277/68 ; C07D263/54 ; C07D487/08 ; A61K31/423 ; A61K31/4439 ; A61P37/02 ; A61K31/497 ; A61K31/428 ; C07D401/14 ; C07D417/14
摘要：
Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.
公开/授权文献
信息查询
